Can patients with advanced bowel cancer take Regorafenib?

Regorafenib(Regorafenib) is an oral multikinase inhibitor approved for refractory colorectal cancer. Although structurally similar to sorafenib, it more effectively inhibits a broader range of key growth receptor pathways, including those that regulate angiogenesis and abnormal cell proliferation. Colon cancer is a cancer that starts in the colon (large intestine) or rectum, the organs that make up the lower part of the digestive system.

Regofenib was evaluated in an international randomized, placebo-controlled, Phase III study involving 760 patients. In this study, improvements in overall survival and progression-free survival were observed. The clinical activity of regorafenibis mainly to inhibit cell growth. 41% of patients achieved disease stabilization, and only 1% of patients achieved remission. Regofenibproved to be tolerable, with side effects characteristic of other small molecule inhibitors.

RegofenibThe original drug has been launched in China and has entered the scope of Class B medical insurance. Reimbursement is limited to patients who meet the indications. SpecificationThe price of each box of 40mg*28 tablets is around RMB 5,000. The reimbursement ratio is different in different regions, and the price after reimbursement is different. The Turkish version of regorafeniboriginal drug specifications 40mg*28 tablets sold overseas is priced around RMB 6,400 per box (the price may fluctuate due to exchange rates). There are also generic regorafenib drugs produced in other countries, and their drug ingredients are basically the same as those of the original drug. The price of a box of 40mg*90 tablets produced by a Bangladesh pharmaceutical factory is around 2,900 yuan (the price may fluctuate due to exchange rates).